



SPONTAN[®] Prescribed by Brisbane Men's Health Expert under the TGA's Special Access Scheme

8 August 2024

Highlights:

- A second men's health expert and clinical key opinion leader ("KOL") in Australia is now authorised to prescribe SPONTAN – a novel treatment for erectile dysfunction ("ED")
- The Company is supporting strategic engagement with a network of healthcare providers familiar with SPONTAN and its clinical benefits, via the TGA's Special Access Scheme ("SAS")
- SPONTAN identified as a new innovation for unmet needs in ED due to:
 - On demand rapid onset of action
 - Decrease in side effect profile

LTR Pharma Limited (ASX:LTP) ("LTR Pharma", "the Company") is pleased to announce that a second medical practitioner has been authorised to prescribe SPONTAN[®] under the Therapeutic Goods Administration's ("TGA") Special Access Scheme ("SAS").

Dr Tom Silva, an expert in men's health, Senior Lecturer in General Practice at the University of Queensland ("UQ") and Director of Kangaroo Point Medical Centre, has begun prescribing SPONTAN for select patients. Kangaroo Point Medical Centre is an innovative comprehensive healthcare facility in Brisbane that offers a wide range of services, with a speciality in erectile dysfunction (ED) and men's health.

Men's health expert, Dr Tom Silva, said: "SPONTAN meets the needs of my patients where regular PDE5 inhibitor tablets do not. Its fast onset of action, ease of use and improved side effect profile make it a valuable addition to our treatment options for erectile dysfunction."

Men's health experts are increasingly interested in SPONTAN's improved side effect profile as an alternative to oral therapies. SPONTAN's nasal spray delivery technology allows for a lower dose of the PDE5 inhibitor than oral tablets, potentially reducing the risk and duration of side effects while maintaining efficacy. The use of SPONTAN at the Kangaroo Medical Centre supports the Company's objectives by expanding its network of healthcare experts familiar with SPONTAN, helping gather additional real-world data and use cases, and increasing awareness within the medical community.

LTR Pharma Chairman, Lee Rodne said: "We are thrilled to see SPONTAN being utilised by medical experts like Dr Silva. This represents another significant step in our strategy to introduce SPONTAN to the market through a carefully managed approach working with knowledgeable medical practitioners."

-Ends-

This announcement has been approved by the Board of Directors.

About LTR Pharma

LTR Pharma is focused on improving men's health, physically and mentally, through the commercialisation of an innovative nasal spray treatment for Erectile Dysfunction. ED is a pressing health issue for millions of men that can negatively impact self-esteem and relationships, across multiple age brackets. LTR Pharma's lead product SPONTAN® is set apart from existing ED therapies by its mechanism of action – intranasal delivery technology of a PDE5 inhibitor. The nasal cavity is a highly vascular part of the body supporting even and rapid absorption of the drug, empowering it to work within 10 minutes or less. LTR Pharma is proudly aiming to restore greater control over the timing, spontaneity, and enjoyment of sexual experiences.

For further information please contact:

Haley Chartres
Media Relations
haley@hck.digital

Peter McLennan
Investor Relations
investors@ltrpharma.com

For personal use only